Chemokine Receptor Antagonists in Combination with Morphine as a Novel Strategy for Opioid Dose Reduction in Pain Management
Abstract
Although opioids are widely prescribed for pain, in many circumstances, they have only modest efficacy. Preclinical studies have shown that chemokines, immune mediators released during tissue injury and inflammation, can desensitize opioid receptors and block opioid analgesia by a process termed “heterologous desensitization.” The present studies tested the hypothesis that in evoked pain, certain chemokine receptor antagonists (CRAs), given with a submaximal dose of morphine, would result in enhanced morphine potency.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jan 01, 2020
- Source ID
- 10.1093/milmed/usz320
Entities
People
- Alan Cowan
- Christopher S. Tallarida
- Ellen B. Geller
- Joseph J. Meissler
- Martin W. Adler
- Saadet Inan
- Scott M. Rawls
- Toby K. Eisenstein
- Xiaohong Chen
Organizations
- National Institutes of Health
- Temple University
- United States Department of Defense